Article Text

Download PDFPDF
Interleukin (IL) 1α, IL1β, IL receptor antagonist, and IL10 polymorphisms in psoriatic arthritis
  1. L Peddle,
  2. C Butt,
  3. T Snelgrove,
  4. P Rahman
  1. Memorial University of Newfoundland, St Clare’s Mercy Hospital, Memorial University of Newfoundland, St John’s Newfoundland, Canada
  1. Correspondence to:
    Dr P Rahman
    St Clare’s Mercy Hospital, 1 South - 154 LeMarchant Rd, St John’s, Newfoundland, Canada A1C-5B8;

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Interleukin (IL) 1 is a potent proinflammatory cytokine that occurs as IL1α and IL1β. The biological activity of IL1α and IL1β is initiated by binding with type 1 IL1 receptor and is inhibited by IL1 receptor antagonist (ILRa).1 IL10 is an anti-inflammatory cytokine that suppresses macrophage production of cytokines and enhances soluble cytokine receptor release.2 These cytokines have been implicated in the pathogenesis of psoriatic arthritis (PsA), as increased expression of IL1 and IL10 has been observed in the synovial fluid and synovial membrane of patients with PsA in comparison with patients with osteoarthritis.3 Given the proposed function of these cytokines in autoimmune disease, we …

View Full Text